New Rochelle, NY — Genetic Engineering & Biotechnology News (GEN) has published its 2016 Top 10 US Biopharma Clusters list. New Jersey/New York is number three on the list, the same position it was on GEN’s 2015 Top 10 list.
This year’s Top 10 are:
This year’s Top 10 are:
- Boston-Cambridge
- San Francisco Bay Area
- New Jersey/New York
- Maryland/DC Metro
- San Diego
- Greater Philadelphia
- Seattle
- Raleigh/Durham
- Los Angeles/Orange County
- Chicagoland
GEN ranks regions based on five criteria:
The combination of the Empire State and Garden State leads the nation in biopharma jobs (127,651 according to JLL), but not in VC funding (fourth with $340.097 million in 25 deals) despite the presence of Wall Street and the financial industry. NY-NJ is second in NIH funding (826 awards totaling $366 million), yet lags behind four other clusters in patents (fifth with 3,522).
New Jersey carries the region in lab space, accounting for more than half (58.5%) of the region’s total 14.194 million square feet—good enough for third, but two notches below a year ago, thanks to stronger demand in Boston/Cambridge and the Bay Area.
New Jersey is also the region’s dominant partner in jobs (60% of the region’s total 127,651) thanks to its heritage pharma industry and a biotech segment that includes giants such as Celgene and Amicus Therapeutics, which acquired Durham, NC-based Scioderm last year.
Biotech is also growing in New York: Regeneron Pharmaceuticals continues to expand in suburban Tarrytown, NY, while New York City’s Accelerator late last year spun out its first two startups, both drug developers, Petra Pharma and Lodo Therapeutics.
- NIH funding — Taken from the publicly available NIH RePORT database, for the current federal fiscal year, from its start on October 1, 2015, through March 27, 2016.
- Venture Capital (VC) funding — Taken from 2015 figures furnished by the publicly available MoneyTree Report.
- Patents — Based on the number of patents containing the word “biotechnology” awarded since 1976 in namesake cities and suburbs where key companies are located.
- Lab space — Based on total-size-of-market figures, in millions of square feet, furnished by the commercial real estate brokerage JLL in its Life Sciences Cluster Reports for 2015.
- Jobs — Based on JLL’s report. While job numbers are ranked this year compared with last year’s Top 10 US Clusters list, less weight had to be given to job totals in regions where GEN has found widespread discrepancies in job figures. However, workforce size was factored in when deciding the ultimate position of a region.
The combination of the Empire State and Garden State leads the nation in biopharma jobs (127,651 according to JLL), but not in VC funding (fourth with $340.097 million in 25 deals) despite the presence of Wall Street and the financial industry. NY-NJ is second in NIH funding (826 awards totaling $366 million), yet lags behind four other clusters in patents (fifth with 3,522).
New Jersey carries the region in lab space, accounting for more than half (58.5%) of the region’s total 14.194 million square feet—good enough for third, but two notches below a year ago, thanks to stronger demand in Boston/Cambridge and the Bay Area.
New Jersey is also the region’s dominant partner in jobs (60% of the region’s total 127,651) thanks to its heritage pharma industry and a biotech segment that includes giants such as Celgene and Amicus Therapeutics, which acquired Durham, NC-based Scioderm last year.
Biotech is also growing in New York: Regeneron Pharmaceuticals continues to expand in suburban Tarrytown, NY, while New York City’s Accelerator late last year spun out its first two startups, both drug developers, Petra Pharma and Lodo Therapeutics.
